SynthesisMedicine2025
Soothing the liver and activating blood circulation for the treatment of chronic prostatitis: A systematic review and meta-analysis.
Synthesis in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research progress on the mechanism, diagnosis, and treatment of exosomal miRNA in chronic prostatitis.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic prostatitis (CP) is a commonly encountered condition within the male urinary system in clinical practice. Studies have shown that the prevalence of CP in China has risen to between 6.0% and 32.9%, with a continuing upward trend. While the method of soothing the liver and activating blood circulation (SLABC) is widely employed in traditional Chinese medicine for treating CP, a thorough analysis of its efficacy is currently lacking. This meta-analysis aims to evaluate the effectiveness and efficiency of SLABC.
methodsWe conducted a search across 8 electronic databases, which included CNKI, Wanfang, VIP, SinoMed, PubMed, Embase, Web of Science, and Cochrane Library, from their inception until October 1, 2023. The primary common outcomes assessed comprised the total effective rate, NIH-CPIS score, and traditional Chinese medicine syndrome score. Two researchers utilized Endnote 20 software for the screening of literature and the extraction of information. The Cochrane rob2.0 collaboration tool was used to evaluate the risk of bias in the trials, while data analysis was carried out using RevMan 5.3 and STATA 15 software.
resultsA total of 22 randomized controlled trials involving 2470 participants were included. The results of the meta-analysis showed that SLABC combined with traditional Western medicine significantly improved the NIH-CPSI score compared with traditional Western medicine alone (mean difference [MD] = -5.23; 95% confidence interval [CI] = -7.30 to -3.15; P < .00001), and its total effective rate was comparable to that of traditional Western medicine (relative risk = 1.09; 95% CI = 0.97-1.23; P = .16). In addition, as a single treatment, SLABC was superior to traditional Western medicine in improving the NIH-CPSI score (MD = -3.67; 95% CI = -5.22 to -2.12; P < .00001), and its effective rate was comparable to that of traditional Western medicine (relative risk = 1.06; 95% CI = 0.92-1.23; P = .40). Furthermore, this approach was more effective than conventional Western medicine in relieving TCM-related symptoms (MD = -0.64; 95% CI = -0.72 to -0.57; P < .00001).
conclusionThe research highlights the effectiveness of SLABC in the treatment of CP. Given the scarcity and subpar quality of pertinent articles, there is a need for more extensive and reliable randomized clinical trials to better evaluate the clinical advantages and long-term efficacy of this therapy for CP.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.